Late relapse of classical Hodgkin lymphoma: an analysis of the German Hodgkin Study Group HD7 to HD12 trials
Purpose: Clinical characteristics, therapeutic approaches, and prognosis of late relapse (LR) in patients with classic Hodgkin lymphoma (cHL) are poorly understood. We performed a comprehensive analysis of LR of Hodgkin lymphoma (LR-HL).MethodsTo estimate the incidence of LR-HL, we retrospectively a...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
February 27, 2017
|
| In: |
Journal of clinical oncology
Year: 2017, Jahrgang: 35, Heft: 13, Pages: 1444-1450 |
| ISSN: | 1527-7755 |
| DOI: | 10.1200/JCO.2016.71.3289 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1200/JCO.2016.71.3289 Verlag, kostenfrei, Volltext: http://ascopubs.org/doi/10.1200/JCO.2016.71.3289 
|
| Verfasserangaben: | Paul J. Bröckelmann, Helen Goergen, Charlotte Kohnhorst, Bastian von Tresckow, Alden Moccia, Jana Markova, Julia Meissner, Andrea Kerkhoff, Wolf-Dieter Ludwig, Michael Fuchs, Peter Borchmann, and Andreas Engert |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1578425476 | ||
| 003 | DE-627 | ||
| 005 | 20230427065631.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180809s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.2016.71.3289 |2 doi | |
| 035 | |a (DE-627)1578425476 | ||
| 035 | |a (DE-576)508425476 | ||
| 035 | |a (DE-599)BSZ508425476 | ||
| 035 | |a (OCoLC)1341016660 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Bröckelmann, Paul Jan |d 1987- |e VerfasserIn |0 (DE-588)1103596209 |0 (DE-627)861402138 |0 (DE-576)470697962 |4 aut | |
| 245 | 1 | 0 | |a Late relapse of classical Hodgkin lymphoma |b an analysis of the German Hodgkin Study Group HD7 to HD12 trials |c Paul J. Bröckelmann, Helen Goergen, Charlotte Kohnhorst, Bastian von Tresckow, Alden Moccia, Jana Markova, Julia Meissner, Andrea Kerkhoff, Wolf-Dieter Ludwig, Michael Fuchs, Peter Borchmann, and Andreas Engert |
| 264 | 1 | |c February 27, 2017 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 09.08.2018 | ||
| 520 | |a Purpose: Clinical characteristics, therapeutic approaches, and prognosis of late relapse (LR) in patients with classic Hodgkin lymphoma (cHL) are poorly understood. We performed a comprehensive analysis of LR of Hodgkin lymphoma (LR-HL).MethodsTo estimate the incidence of LR-HL, we retrospectively analyzed 6,840 patients with cHL included in the German Hodgkin Study Group trials HD7 to HD12. Patients who experienced a relapse > 5 years into remission were compared with patients in continued remission for > 5 years and with those who experienced a relapse ≤ 5 years after first diagnosis.ResultsWith a median observation time of 10.3 years, 141 incidences of LR-HL were observed. Cumulative incidences at 10, 15, and 20 years rose linearly and were 2.5%, 4.3%, and 6.9%, respectively. The standardized incidence ratio for HL with respect to age- and sex-matched German reference data was 84.5 (95% CI, 71.2 to 99.7). LR-HL was more frequently observed in patients with early-stage favorable than unfavorable or advanced stage at first diagnosis (15-year cumulative incidence, 5.3% v 3.9% and 3.9%, respectively; P = .01). Overall survival from first diagnosis was worse after LR compared with nonrelapse survivors (10-year estimate, 95.8% v 86.1%; hazard ratio, 2.5; 95% CI, 1.7 to 3.5; P < .001). In patients with LR-HL, survival was better compared with 466 patients with earlier relapse (hazard ratio, 0.6; 95% CI, 0.4 to 0.9, P = .01). Forty-four percent and 49% of patients with LR-HL and earlier relapse, respectively, received stem cell transplantations.ConclusionApart from treatment-associated adverse effects, survivors after initially successful therapy for cHL are at an 85-fold risk for recurrence of disease compared with the general German population. After risk-adapted treatment strategies, especially in early-stage favorable HL, regular clinical follow-up is recommended for timely detection of LR-HL. With adequate treatment, prognosis of LR-HL is better compared with early relapses. | ||
| 700 | 1 | |a Meißner, Julia |e VerfasserIn |0 (DE-588)1236765966 |0 (DE-627)176254850X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology |d Alexandria, Va. : American Society of Clinical Oncology, 1983 |g 35(2017), 13, Seite 1444-1450 |h Online-Ressource |w (DE-627)313116962 |w (DE-600)2005181-5 |w (DE-576)090887018 |x 1527-7755 |7 nnas |a Late relapse of classical Hodgkin lymphoma an analysis of the German Hodgkin Study Group HD7 to HD12 trials |
| 773 | 1 | 8 | |g volume:35 |g year:2017 |g number:13 |g pages:1444-1450 |g extent:7 |a Late relapse of classical Hodgkin lymphoma an analysis of the German Hodgkin Study Group HD7 to HD12 trials |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1200/JCO.2016.71.3289 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u http://ascopubs.org/doi/10.1200/JCO.2016.71.3289 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180809 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 1236765966 |a Meißner, Julia |m 1236765966:Meißner, Julia |d 910000 |d 910100 |e 910000PM1236765966 |e 910100PM1236765966 |k 0/910000/ |k 1/910000/910100/ |p 7 | ||
| 999 | |a KXP-PPN1578425476 |e 3020508193 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 09.08.2018"],"recId":"1578425476","id":{"eki":["1578425476"],"doi":["10.1200/JCO.2016.71.3289"]},"title":[{"title_sort":"Late relapse of classical Hodgkin lymphoma","title":"Late relapse of classical Hodgkin lymphoma","subtitle":"an analysis of the German Hodgkin Study Group HD7 to HD12 trials"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedDisp":"February 27, 2017","dateIssuedKey":"2017"}],"language":["eng"],"relHost":[{"id":{"issn":["1527-7755"],"eki":["313116962"],"zdb":["2005181-5"]},"title":[{"title_sort":"Journal of clinical oncology","title":"Journal of clinical oncology","subtitle":"JCO : an American Society of Clinical Oncology journal"}],"note":["Fortsetzung der Druck-Ausgabe","Gesehen am 22.05.23"],"disp":"Late relapse of classical Hodgkin lymphoma an analysis of the German Hodgkin Study Group HD7 to HD12 trialsJournal of clinical oncology","physDesc":[{"extent":"Online-Ressource"}],"part":{"issue":"13","volume":"35","text":"35(2017), 13, Seite 1444-1450","pages":"1444-1450","extent":"7","year":"2017"},"origin":[{"dateIssuedDisp":"1983-","dateIssuedKey":"1983","publisherPlace":"Alexandria, Va. ; Baltimore, Md. [u.a.]","publisher":"American Society of Clinical Oncology ; Lippincott Williams & Wilkins"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"titleAlt":[{"title":"official journal of the American Society of Clinical Oncology"},{"title":"JCO"},{"title":"Journal of clinical oncology legacy archive (ASCO)"}],"pubHistory":["1.1983 -"],"corporate":[{"role":"isb","display":"American Society of Clinical Oncology","roleDisplay":"Herausgebendes Organ"}],"recId":"313116962"}],"physDesc":[{"extent":"7 S."}],"person":[{"family":"Bröckelmann","roleDisplay":"VerfasserIn","given":"Paul Jan","display":"Bröckelmann, Paul Jan","role":"aut"},{"roleDisplay":"VerfasserIn","family":"Meißner","display":"Meißner, Julia","role":"aut","given":"Julia"}],"name":{"displayForm":["Paul J. Bröckelmann, Helen Goergen, Charlotte Kohnhorst, Bastian von Tresckow, Alden Moccia, Jana Markova, Julia Meissner, Andrea Kerkhoff, Wolf-Dieter Ludwig, Michael Fuchs, Peter Borchmann, and Andreas Engert"]}} | ||
| SRT | |a BROECKELMALATERELAPS2720 | ||